A research study
titled, “Gout
Therapeutics Market by Product Type and Disease Condition - Global Industry
Analysis and Forecast to 2025” published by Crystal Market Research, states
that the gout therapeutics market is projected to be around $8 billion by 2025.
Gout is the most common form of inflammatory arthritis
worldwide. It is characterized by pain, redness and tenderness in joints. Gout
is crystal-deposition disease due to over production of uric acid above
saturation level leading to crystal formation. The incidence of gout has been
increasing rapidly worldwide with every six individuals in 1,000 suffering from
gout and its related complications based on study conducted by US National
Health and Nutrition Examination Surveys (NHANES). Gout conditions are more
prevalent in men between ages of 40 to 50 whereas in women chances of
developing gout infections increases after onset of menopause. Hence, rising
incidence of gout will demand more advanced drugs for treating gout and its
related conditions. Gout therapeutic market is expected to witness significant
growth due to rise in elderly population, rise in obesity and approval of
effective gout therapies.
Browse full research report with TOC on “Gout
Therapeutics Market by Product Type and Disease Condition - Global Industry
Analysis and Forecast to 2025” at: http://www.crystalmarketresearch.com/report/gout-therapeutics-market
Non-steroidal anti-inflammatory drugs (NSAIDs) segment
dominated the global market in 2016. This can be attributed to number of
factors such as low cost of NSAIDs, easy availability, and ability to induce
anti-inflammatory response faster than other available drugs for gout attacks. Additionally,
introduction of advanced and new drugs (such as TMX 67, Krystexxa, and
Zurampic) for gout treatment, increase in adoption rate of gout drugs, and huge
investments for drug designing and development are set to further drive the
demand for NSAIDS. Corticosteroids segment is expected to witness slow growth
due to reoccurrence of gout attack after withdrawal of steroids/drugs. Urate
lowering drugs segment has seen tremendous growth in last few years due to
their ability of producing strong anti-inflammatory response by inhibiting
xanthine oxidase.
In 2016, the global market was dominated by North America.
This large share can be attributed to number of factors such as rise in
incidence of gout infections and high adoption of technologically advanced
products. European market is expected to grow at considerable CAGR during the
forecast period, due to increased number of drug approvals. For instance, in
February 2016, AstraZeneca’s product, Zurampic in combination of xanthine
oxidase inhibitor, was approved by European Union. Therefore, introduction of urate-lowering
agents in European market will drive the market growth.
Request a sample copy of Gout Therapeutics Market
Research Report @ http://www.crystalmarketresearch.com/report-sample/HC055
Some of the major companies are Merck& Co. Inc.; GlaxoSmithKline
plc; Teijin Pharma Ltd.; Regeneron Pharmaceuticals; Novartis AG; Savient
Pharmaceuticals; Takeda Pharmaceutical Company Ltd.; and AstraZeneca plc.
Market is expected to grow further by national and international collaborations
and partnership for developing safety profile in treating such conditions. For instance,
in Dec 2015, Horizon Pharma plc acquires Crealta Holdings LLC for developing
and commercialization of medicines such as KRYSTEXXA for treating refractory
gout disease.
Key
Findings of the Research Study:
·
NSAIDs segment dominated the global market
with almost two-fourth share in 2016, due to low cost and ability to produce
strong anti-inflammatory response.
·
Colchicine segment accounted for significant
market share in 2016, due their ability to inhibit inflammatory action of
Neutrophils.
·
Chronic gout dominated the global market in
2016 owing to high prevalence of chronic gout infections worldwide.
·
U.S. dominated the global market in 2016, due
to high adoption of advanced drugs and treatment methods.
·
Asia-Pacific is poised to grow at a high CAGR
during the forecast period, owing to increase in population base suffering from
gout infections and rise in adoption rate of gout therapies.
Inquire more about this report at: http://www.crystalmarketresearch.com/send-an-enquiry/HC055
Gout therapeutic market
is segmented as follows –
By Product Type:
· Colchicines
· Corticosteroids
· NSAIDs
- Urate-lowering Agents
By Disease Condition:
· Acute Gout
- Chronic Gout
By Region:
· North America
- U.S
- Canada
- Mexico
· Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
· Asia-Pacific
- Japan
- China
- Australia
- India
- South Korea
- Rest of Asia-Pacific
· Rest of the World
- Brazil
- South Africa
- Saudi Arabia
- Turkey
- United Arab Emirates
- Others
Get Customization in the Report At: http://www.crystalmarketresearch.com/customization/HC055
Related Reports:
Anti-Inflammatory
Therapeutics Market by Indication and Drug Class - Global Industry Analysis and
Forecast to 2025: http://www.crystalmarketresearch.com/report/anti-inflammatory-therapeutics-market
Global Respiratory
Care Devices Market by Disorder and End User - Global Industry Analysis and
Forecast to 2025: http://www.crystalmarketresearch.com/report/global-respiratory-care-devices-market
About Crystal
Market Research
Crystal Market Research is a U.S. based market research
and business intelligence company. Crystal offers one stop solution for market
research, business intelligence, and consulting services to help clients make
more informed decisions. It provides both syndicated as well as customized
research studies for its customers spread across the globe. The company offers
market intelligence reports across a broad range of industries including
healthcare, chemicals & materials, technology, automotive, and energy.
Contact:
Akhil
V.
304
South Jones Blvd, Suite 1896,
Las
Vegas NV 89107,
United
States
Toll
Free: +1-888-213-4282
Website: http://www.crystalmarketresearch.com
No comments:
Post a Comment